Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3

被引：32

作者：

Chen, Jack J. ^{[1
]}

Thakur, Kumar D. ^{[1
]}

Clark, Michael P. ^{[1
]}

Laughlin, Steven K. ^{[1
]}

George, Kelly M. ^{[1
]}

Bookland, Roger G. ^{[1
]}

Davis, Jan R. ^{[1
]}

Cabrera, Edward J. ^{[1
]}

Easwaran, Vijay ^{[1
]}

De, Biswanath ^{[1
]}

Zhang, Y. George ^{[1
]}

机构：

[1] Procter & Gamble Pharmaceut, Hlth Care Res Ctr, Mason, OH 45040 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2006年 / 16卷 / 21期

关键词：

tyrosine kinase inhibitor; JAK3; JAK2; pyrimidine;

D O I：

10.1016/j.bmcl.2006.08.022

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A new class of pyrimidine-based Janus tyrosine kinase 3 (JAK3) inhibitors are described. Many of these inhibitors showed low nanomolar activity against JAK3. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：5633 / 5638

页数：6

共 8 条

[1] Mapping the kinase domain of Janus Kinase 3 [J].

Adams, C ;

Aldous, DJ ;

Amendola, S ;

Bamborough, P ;

Bright, C ;

Crowe, S ;

Eastwood, P ;

Fenton, G ;

Foster, M ;

Harrison, TKP ;

King, S ;

Lai, J ;

Lawrence, C ;

Letallec, JP ;

McCarthy, C ;

Moorcroft, N ;

Page, K ;

Rao, S ;

Redford, J ;

Sadiq, S ;

Smith, K ;

Souness, JE ;

Thurairatnam, S ;

Vine, M ;

Wyman, B .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (18) :3105-3110

[2]

Kudlacz E, 2004, AM J TRANSPLANT, V4, P51, DOI 10.1046/j.1600-6143.2003.00281.x

[3] Of genes and phenotypes:: the immunological and molecular spectrum of combined immune deficiency.: Defects of the γc-JAK3 signaling pathway as a model [J].

Notarangelo, LD ;

Giliani, S ;

Mazza, C ;

Mella, P ;

Savoldi, G ;

Rodriguez-Pérez, C ;

Mazzolari, E ;

Fiorini, M ;

Duse, M ;

Plebani, A ;

Ugazio, AG ;

Vihinen, M ;

Candotti, F ;

Schumacher, RF .

IMMUNOLOGICAL REVIEWS, 2000, 178 :39-48

[4] Targeting the Jak/STAT pathway for immunosuppression [J].

O'Shea, JJ .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 :67-71

[5] A new modality for immunosuppression: Targeting the JAK/STAT pathway [J].

O'Shea, JJ ;

Pesu, M ;

Borie, DC ;

Changelian, PS .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (07) :555-564

[6] INTERFERON-INDUCED NUCLEAR SIGNALING BY JAK PROTEIN-TYROSINE KINASES [J].

SILVENNOINEN, O ;

IHLE, JN ;

SCHLESSINGER, J ;

LEVY, DE .

NATURE, 1993, 366 (6455) :583-585

[7] Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin [J].

Stepkowski, SM ;

Erwin-Cohen, RA ;

Behbod, F ;

Wang, ME ;

Qu, X ;

Tejpal, N ;

Nagy, ZS ;

Kahan, BD ;

Kirken, RA .

BLOOD, 2002, 99 (02) :680-689

[8] The role of Jak3 in lymphoid development, activation, and signaling [J].

Thomis, DC ;

Berg, LJ .

CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (04) :541-547

← 1 →